The market experienced revenue growth of 5.1 percent, driven mainly by premium lenses.
This amount compares with $215 million in 2012 and $350 million in 2011.
Global demand for refractive surgery continued to suffer in 2013 from a combination of economic malaise and bad press regarding the risks of LASIK.
A growing number and variety of instruments were offered.
In the retinal pharma market, 2013 brought signs of a maturing anti-VEGF market sector; in the glaucoma pharma market, generic medications continued to significantly affect revenue.
US regulators were busy in 2013 with a host of approvals for new products, supplemental labeling, and generic versions of drugs.
The $8.7 billion acquisition accounted for an estimated 87 percent of all acquisition funds in the ophthalmic market in 2013.
The market currently generates roughly $4.2 billion in annual revenue at the manufacturer’s level.
We forecast global revenues for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT devices—along with maintenance, accessories, and endoprobes, to total $380 million in 2013.
The bills are expected to be taken up by the full House and Senate in the coming weeks.
Deal was for $70 million in cash.
Drugmakers' influence on doctors made headlines recently in two cases involving companies that market to ophthalmologists.
You are not currently logged in.
©2017 Market Scope
Lost your Password